Fucoidan is known to have various pharmacological effects, including antitumor activity. Although it has potential as a therapeutic agent for cancer cells, the anti-senescence effects and detailed mechanism of action remain poorly understood in normal hepatic cells. We investigated the anticancer functions of fucoidan using HepG2 cells as well as the mechanisms mediating the anti-senescent actions in Chang liver cells. Fucoidan effectively inhibited HepG2 cell viability and induced apoptosis. Also, fucoidan-induced G 1 phase arrest was caused by the activity of the p16
Introduction
Fucoidan is a polysaccharide from the cell wall of brown seaweed containing a substantial percentage of L-fucose and sulfate ester groups (1) . It has numerous pharmacological properties as an anti-coagulant, anti-tumor, anti-inflammatory and anti-oxidant agent (2) (3) (4) (5) . In particular, its anti-tumor activity has recently attracted considerable attention (6,7) as a potential therapeutic agent for cancer. However, the antisenescence effects and detailed mechanism of action remains poorly understood in normal hepatic cells.
Treatment options for liver cancer focus primarily on chemotherapy (8) . While these chemotherapeutic regimens are well established, the major drawback remains their limited specificity for the tumor site. Chemotherapeutic drugs, such as cisplatin, induce senescence by enhancing the activity of the tumor suppressor p16
INK4a in cancer and normal cells, which results in increased toxicity to normal cells, which require balanced expression of p16
INK4a for growth and differentiation to maintain cell homeostasis. Thus, cancer cell-specific expression of p16
INK4a would be a valuable therapeutic strategy for cancer treatment (9) . Cellular senescence, leading to cell death through the prevention of regular cell renewal, is associated with the upregulation of p16
INK4a in most mammalian tissues (10) . This process requires activation of several signaling pathways, including phosphorylated retinoblastoma (pRb) and p14 Arf -p53 (11) . Phosphorylation of the Rb protein results in increased p16
INK4a expression to inhibit cyclin-dependent kinase (Cdk) 4/6. This leads to increased levels of hypophosphorylated Rb that decrease p16
INK4a expression (12) . Although there is a feedback loop between p16 INK4a and Rb, p16
INK4a expression does not change appreciably during the cell cycle to correlate with the activation status of Rb (13) . However, increased expression of p16
INK4a leads to senescence and cancer cells inactivate p16
INK4a by homozygous deletion or hypermethylation to overcome its effects. The tumor suppressor p14
Arf (p19 Arf in mouse cells) has emerged as an interesting candidate linking transformation and senescence responses. Arf is the second protein, in addition to p16, expressed from the INK4a/Arf locus, but bears no homology to p16 or any other cyclin-dependent kinase inhibitors (CKIs) (14) . Arf neutralizes the ability of MDM2 to promote p53 degradation, leading to the stabilization and accumulation of p53 (15) . Increased expression of Arf also causes growth arrest, one of the hallmarks of premature senescence (16 Arf directly regulates p53 and indirectly regulates pRb (Fig. 1) . Inactivation of the p53 and pRb pathways through a variety of mechanisms occurs in the majority of, if not all, human cancers. Although these pathways play important roles in differentiation, development and DNA repair, the INK4a/Arf locus responds largely to aberrant growth or oncogenic stress. Therefore, the INK4a/Arf locus appears to function as a dualpronged brake to malignant growth, which engages two potent anti-proliferative pathways represented by p16
INK4a -pRb and p14
Arf -p53 signaling (17) . The p38 mitogen-activated protein kinase (MAPK) pathway regulates cellular processes that directly contribute to tumor suppression, including oncogene-induced senescence and replicative senescence (18) , as well as proliferation and tumorigenesis (19) . Senescence is also accompanied by markers associated with replicative exhaustion of normal cells, such as senescence-associated β-galactosidase (SA-β-gal) activity and the induction of p21, p16
INK4a and/or p14 Arf (16, 20) . A previous study suggested that expression of α-2-macroglobulin (α 2 M) can be used as a biomarker of aging in cultured human fibroblasts, can be measured easily by reverse-transcriptase polymerase chain reaction (RT-PCR) with a limited sample, and is a more suitable biomarker candidate of aging then the well-known senescence-associated genes such as p16 INK4a (21) . In this study, we determined the expression of α 2 M as a biomarker of cellular senescence to assess the anti-senescence effects of fucoidan in normal human liver cells.
Materials and methods
Fucoidan. Commercially available fucoidan purified form F. vesiculosus (F5631) was purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA).
Cell culture. The human hepatocellular carcinoma cell line (HepG2; HB-8065) and the human normal liver cell line (Chang-L; CCL-13) were obtained from the American Type Culture Collection (ATCC, GA, USA). Cells were cultured in MEM medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37˚C in a humidified 5% CO 2 incubator.
Cell viability assay. Cell viability was determined by the Cyto™ cell viability assay kit (LPS solution, Daejeon, Korea). Cells were seeded at a density of 1x10 4 cells/well in a 96-well plate. After 24 h, the cells were treated with the phosphate-buffered saline (PBS) vehicle or 100, 250 and 500 µg/ml fucoidan. The Cyto solution was added to each well and incubated for 4 h. The formazan product was estimated by measuring absorbance at 450 nm in a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). 6 cells/well were treated with varying concentrations of fucoidan for 24 h. Cells were harvested by trypsinization, washed twice with PBS, and re-suspended in Annexin V and 7-aminoactinomycin D (7-AAD) for 20 min at room temperature in the dark. The cells were evaluated immediately by Muse cell analyzer. The percentage of apoptotic cells was assessed using the Muse™ software.
Western blotting. Samples were analyzed by western blotting, as described previously (20) . Whole-cell lysates were prepared by lysing cell pellets in a NETN lysis buffer [0.5% Nonidet P-40, 1 mM EDTA, 50 mM Tris (pH 7.4), 12 mM NaCl, 1 mM DTT, 10 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF]. Samples (50 µg) were resolved by SDS-PAGE and transferred to Immobilion-P transfer membranes (Millipore Co., MA USA). The primary antibodies used included monoclonal anti-p16
INK4a , polyclonal anti-Cdk4 and -Cdk6, polyclonal anti-p21, polyclonal anti-p38, monoclonal anti-p-p38, polyclonal anti-p53 and polyclonal anti-pRb (1:1,000, Santa Cruz Biotechnology, Inc., TX, USA). Membranes were washed and incubated with the corresponding HRP-conjugated secondary antibody at 1:10,000. Bound secondary antibody was detected using a chemiluminescence substrate (Advansta, Menlo Park, CA, USA) and visualized on GeneSys imaging system (SynGene Synoptics, Ltd., London, UK).
Real-time PCR. Cells were harvested 24 h after treatment with PBS, 100, 250 or 500 µg/ml fucoidan. Total-RNA was extracted from HepG2 and Chang-L cells using the QIAzol lysis reagent (Qiagen Sciences, Inc., Germantown, MD, USA). RNA quality was evaluated by measuring absorbance at 260 and 280 nm to calculate the concentration and to assess the purity of RNA, respectively. Agarose electrophoresis was used to detect RNA purity and integrity.
The GoScript™ Reverse Transcription System (Promega Corp., Madison, WI, USA) was used to prepare cDNA according to the manufacturer's instructions; the samples were stored at -20˚C. The quality of cDNA was assessed by amplifying an internal reference gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), by PCR and the results were confirmed by 2% agarose gel electrophoresis. The products were examined by computerized gel imaging system (Bio-Rad, Hercules, CA, USA).
Quantitative PCR was conducted in 20 µl reactions containing QuantiMix SYBR kit (PhilKorea Technology, Inc., Daejeon, Korea) using the Illumina Eco™ real-time PCR system (Illumina, Inc., Hayward, CA, USA). The oligonucleotide primers for p16 INK4a , p14 Arf , p21, p53, p38, α 2 M and GAPDH are shown in Table I . Reaction mixtures were incubated for an initial denaturation at 95˚C for 10 min followed by 40 cycles of 95˚C for 15 sec, 55˚C for 15 sec and 72˚C for 15 sec. For each sample, the expression level of each mRNA was quantified as the cycle threshold difference (∆C t ) to GAPDH mRNA. All reactions were performed in triplicate and repeated with two independent experiments. Statistical analysis. SPSS software (Chicago, IL, USA) was used to perform the statistical analysis. For comparisons for more than two groups, data were analyzed by one-way analysis of variance (ANOVA), followed by Duncan's test for multiple comparisons. For all tests, P<0.05 was considered to indicate significance.
Results

Effects of fucoidan on cell viability.
To verify the effects of fucoidan on cell viability, cells were treated with fucoidan at the concentrations indicated for 24 h (Fig. 2) . Compared to the untreated controls, Chang-L cells exhibited no cytotoxicity at concentrations between 0 and 500 µg/ml. In contrast, proliferation of HepG2 cells was dose-dependently inhibited by fucoidan treatment (250 µg/ml, 79.75±9.94% inhibition; 500 µg/ml, 62.43±1.0% inhibition). Thus, the ability of fucoidan to inhibit proliferation was significantly different between HepG2 and Chang-L cells.
Effects of fucoidan on apoptosis.
To determine whether the cytotoxicity of fucoidan was caused by apoptosis, Annexin V/7-AAD double-staining was performed. In fucoidan-treated HepG2 cells, the percentage of the early apoptotic cells, as well as the total percentage of Annexin V-positive cells indicating INK4a -pRb and p14
Arf -p53 pathways mediate the hyperproliferative stress response in cancer. Hyperproliferative signals including cellular stress, DNA damage and oncogenes lead to increased levels of p16
INK4a and p14
Arf . p16
INK4a inhibits Cdk4/6 activity, inducing Rb phosphorylation, which leads to cell cycle arrest. p14
Arf inhibits MDM2-mediated degradation of p53, which activates p21, a Cdk inhibitor. Through an unknown mechanism, active p38 MAPK also induces the expression of p16
Arf , which together with the p53-p21 cascade, causes premature senescence that serves as a tumor-suppressing defense mechanism in vitro and in vivo. GAPDH  TGC ACC ACC AAC TGC TTA GC  GGC ATG GAC TGT GGT CAT GAG  p16   INK4a   GCC CAA CGC CCC GAA CTC TTT C  TGA AGC TAT GCC CGT CGG TCT G  p14   Arf   GGA GGC GGC GAG AAC AT  TGA ACC ACG AAA ACC CTC ACT  p53  GAG GGA TGT TTG GGA GAT GTA A  CCC TGG TTA GTA CGG TGA AGT G  p38  GAG GAT GCC AAG CCA TG  TCT TAT CTG AGT CCA ATA CAA GCA TC  p21 CCG CGA CTG TGA TGC GCT AAT G CTC GGT GAC AAA GTC GAA GTT C α 2 M TTG TCA GTG ACG TTT GCC TC CAA ACT CAT CCG TCT CGT AG late apoptotic cells, was significantly increased in a dosedependent manner (Fig. 3) . In Chang-L cells, the percentage of apoptotic cells did not differ between fucoidan-treated groups and controls (data not shown). These results indicate that fucoidan had a strong antitumor effect on hepatocellular carcinoma cells and is a potent apoptosis-inducing agent.
Effects of fucoidan on the cell cycle. To determine whether fucoidan affected the cell cycles of HepG2 and Chang-L cells, we performed cell analysis 24 h after fucoidan treatment. Treatment with 500 µg/ml fucoidan led to a significant decrease in the production of S and G 2 /M phases and G 0 /G 1 phase arrest in HepG2 cells (43.12% in W/O, 77.78% in fucoidan-treated samples; P<0.05). Treatment at concentrations between 0 and 500 µg/ml did not significantly change the cell cycles of Chang-L cells (Table II) . These results suggest that the anti-proliferative effect of fucoidan on HepG2 cells can be attributed to a blocking of the G 0 /G 1 phase of the cell cycle.
Expression of p16
INK4a -pRb pathway-related proteins in fucoidan-treated cells. To evaluate the mechanism underlying the tumor-suppressing activity of fucoidan, we examined the expressions of p16
INK4a , Cdk4/6 and pRb by western blotting in HepG2 cells after treatment with fucoidan for 24 h. We further explored the mechanism of this antitumor action by evaluating mRNA expression by real-time PCR.
The p16 INK4a is a key component of the Rb pathway that can inhibit the activity of Cdks, thereby preventing proliferating cells from entering the S phase (22) . As shown in Figs. 4A and 5, 250 and 500 µg/ml fucoidan significantly increased p16
INK4a expression levels in HepG2 cells (P<0.05). We deter- mined that fucoidan likely activates the Cdk4 and pRb pathway by triggering p16 INK4a overexpression and maintaining the hypophosphorylated state of Rb (Figs. 4A and 5) . Therefore, we determined that p16
INK4a arrests cells in the G 1 phase by inhibiting the activities of Cdk4 and pRb (Table II) .
To identify the effects of fucoidan that regulate cell growth arrest and thus promote cellular senescence in Chang-L cells, we analyzed p16
INK4a /Cdk4 and Cdk6/pRb, which are primarily responsible for inhibiting cell growth and inducing cellular senescence (23) . The activation of p16 INK4a is a common step in the induction of senescence arrest. However, in Chang-L cells treated with fucoidan, overexpression of p16
INK4a protein was not detected (Figs. 4B and 6 ). In addition, Cdk4-dependent activation of pRb, which is important for cell cycle arrest, did not significantly change (Fig. 4) . The p16
INK4a also links several senescence-initiating signals to p53 activation. However, fucoidan resulted in a significant downregulation of p16 INK4a compared to non-treated Chang-L cells when analyzed by real-time PCR (Fig. 6) .
Expression of p14
Arf -p53 pathway-related proteins in fucoidantreated cells. The p14
Arf and p16 INK4a are key tumor suppressor genes that inactivate p53. To explore the effects of the p14 Arf -p53 pathway on maintaining senescence arrest by fucoidan, we analyzed the expression of the pathway in Chang-L cells by western blotting and real-time PCR. We further investigated the tumor suppressor activity of fucoidan in HepG2 cells through the p14 Arf -p53 pathway.
Although p14
Arf protein expression was not detected by western blotting, the expression of p14
Arf mRNA was detected in both HepG2 and Chang-L cells. Real-time PCR determined that fucoidan significantly increased p14
Arf mRNA expression in HepG2 cells at concentrations of 250 and 500 µg/ml (Fig. 5 ) but significantly decreased expression in Chang-L cells (Fig. 6) . Hence, fucoidan suppresses p14
Arf expression as well as p16
INK4a expression in Chang-L cells. In parallel experiments, treatment of HepG2 cells with 250 and 500 µg/ml fucoidan increased the protein expression of p53 and p21, which are involved in the activation of tumor suppressors (Fig. 4A) , and upregulated p53 mRNA. Furthermore, fucoidan-induced p53 mRNA resulted in upregulation of p21 mRNA (Figs. 4A and 5). In Chang-L cells, the mRNA levels of p14
Arf and p21, which are involved in cellular senescence, were significantly lower at concentrations >100 µg/ml (Fig. 6) . However, fucoidan treatment did not significantly affect p53 mRNA compared to controls (Fig. 6) . Thus, decreased expression of p14
Arf and p21 induced senescence arrest due to inactivation of the p53 pathway, and significant changes in the cell cycle were observed after treatment with fucoidan (Fig. 4B , Table II) .
Expression of p38 MAPK in fucoidan-treated cells. p38 MAPK can trigger premature senescence in primary cells and permanent oncogene-induced proliferative arrest, which has been proposed as an anti-tumorigenic defense mechanism that induces p53 phosphorylation and upregulation of p16
INK4a (18) . We defined whether activation of p38 MAPK mediated tumor suppression and replicative senescence, and examined the relationship between fucoidan-stimulated activation of p16
INK4a / p53 and p38 MAPK in HepG2 and Chang-L cells (Fig. 1) . We further determined whether the expression of phosphorylated p38 MAPK increased in both cell types. Fucoidan dosedependently elevated phospho-p38 MAPK (Fig. 4A ) and p38 MAPK gene expression in HepG2 cells (Fig. 7) . In contrast, it did not significantly affect p38 and phospho-p38 protein levels in Chang-L cells (Fig. 4B) .
Correlation analysis was used to examine the relevance of p38 MAPK, p16
INK4a and p53 expression after fucoidan treatment of HepG2 and Chang-L cells. Positive correlations between p38 MAPK and p16
INK4a /p53 were found in HepG2 cells (Fig. 9 ), whereas p38 MAPK was closely related with p16
INK4a in Chang-L cells (data not shown). However, the levels of p53 mRNA were not associated with p38 MAPK (data not shown).
Gene expression of α 2 M as an aging biomarker.
The expression of α 2 M can easily be measured by real-time PCR and it is a more suitable biomarker candidate of aging then well-known senescence-associated genes such as p16 INK4a .
Compared to controls, the mRNA level of α 2 M significantly increased in HepG2 cells treated with fucoidan in a manner similar to p16
INK4a expression (Fig. 8) . In Chang-L cells, fucoidan treatment dose-dependently decreased α 2 M expression, but not p16
INK4a . When we compared HepG2 and Chang-L cells, a significant difference in α 2 M mRNA levels was noted after incubation with 250 and 500 µg/ml fucoidan (Fig. 8) .
Discussion
Natural products have played a pivotal role in the quest to develop novel chemotherapeutic agents with enhanced specificity and potency in liver cancer. Many marine compounds have chemopreventive and chemotherapeutic effects through various cell-signaling pathways involved in the transduction of mitogenic signals and subsequent regulation of cell growth and proliferation (24) . The diverse biological activities of fucoidan have been studied intensively and include anti-oxidant, immunomodulatory, anti-virus and anti-coagulant effects (3, 4, 25, 26) . In particular, the anti-tumor activity has recently attracted considerable attention and several studies have addressed its anti-carcinogenic effects (7) . Fucoidan inhibits the growth of a wide variety of tumor cells (3, 26) , which has become a focus of great interest because it is expected to be a new candidate for low-toxicity cancer therapy (7) .
Cancer cells need to evade anti-proliferative signals that negatively regulate growth and proliferation. Cancer cells can avoid this control step by losing the physiological function of the pRb, which controls all anti-proliferative signals (24) . Consequently, natural product compounds that inhibit constitutive hyper-phosphorylation of pRb contribute efficiently to the reestablishment of regulated growth in cancer (24) . In cancer cells, the hyper-proliferation stress response tends to be suppressed, allowing the continued proliferation of cells carrying overactive mitogenic signals. Hyper-proliferation signals lead to increased levels of p16
INK4a and p14 Arf resulting in cell cycle arrest or cell death through the pRb and p53 pathways. In many cell types, particularly in humans, the Cdk inhibitor p16
INK4a contributes to the cell cycle arrest that occurs after hyper-proliferation stress. Thus, the loss of p16
INK4a , which occurs in many cancers, helps abolish this response in some cell types. Some cancer-associated chromosomal deletions disrupt both p16
INK4a and p14 Arf genes, thereby knocking out regulators of both the pRb and p53 pathways. Loss of p53 function is a remarkably common event in tumor cells because it allows cell proliferation to continue following different forms of stress and DNA damage (27) . In addition, the INK4/Arf locus gene, p16
INK4a and p14 Arf (or p19 Arf in mouse), which is upregulated during aging (28) has been genetically linked to numerous aging-associated diseases in humans (29) . Accordingly, we anticipated that marine compounds such as fucoidan could have chemopreventive and chemotherapeutic effects by regulating the expression of p16 INK4a , p14 Arf and p53 in cancer cells. Fedorov et al showed that the natural marine chamigranetype sesquiterpenoid dactylone inhibited cyclin D, Cdk4 expression and pRb phosphorylation (30) . The inhibition of these cell cycle components was followed by cell cycle arrest at the G 1 -S transition, with subsequent p53-independent apoptosis in human cancer cells. Park et al described the suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of the Cdk inhibitor p16
INK4a and downregulation of pRb phosphorylation (31) .
Interestingly, the wild-type p53 gene is often inactivated in HepG2 cells (32) . However, we determined that fucoidan significantly upregulated the expression of p53 in HepG2 cells, while simultaneously inducing apoptosis with inhibition of cellular proliferation (Figs. 2 and 3) . Real-time PCR and western blotting studies correlated increased mRNA and protein expression for p16 INK4a and p21 (Figs. 4A and 5 ). These results suggest that the growth arrest in hepatocellular carcinoma cells results from an increase in p53-mediated p21 expression as cells enter senescence, followed by a sustained elevation of p16
INK4a (Fig. 5) .
The p21 gene is a cell cycle inhibitor and tumor suppressor downstream of p53. When cells are damaged, p53 and p21 act together to inactivate the cyclin-Cdk complex, which could mediate G 1 and G 2 /M arrest (33) . In this study, induction of G 1 arrest by fucoidan was accompanied by a large accumulation of p53 and p21. In particular, p21 sustains hypophosphorylated Rb and arrests cells in the G 1 phase. Therefore, we can deduce that the anti-proliferative effect of fucoidan regulates pRb-or p53-mediated cell cycle arrest in HepG2 cells (Table II) . This supports the idea that p16
INK4a -pRb-mediated G 1 arrest by fucoidan is elicited by p53 and p21 upregulation.
Fujii et al suggested that the expression of INK4a/Arf locus genes p16
INK4a and p14 Arf could be related to cellular senescence and apoptosis and reported that expression of this locus was increased by valproic acid treatment and induced apoptosis in sphere cells from rat sarcomas (34) . We also demonstrated that fucoidan caused induction of apoptosis and tumor suppression by p16
INK4a and p14 Arf overexpression in HepG2 cells but did not affect normal Chang-L cells. Resistance to apoptosis by cancer cells can be acquired through a variety of strategies, including p53 tumor suppressor gene inactivation. The p53 can lead to induction of the apoptotic cascade (24) . However, numerous studies have determined that p38 MAPK may be correlated with apoptosis in various cancer cells (35) . The p38 MAPK can regulate cell proliferation and apoptosis through phosphorylation of p53, increased c-myc expression and regulation of Fas/FasL-mediated apoptosis (36) . The impact of p38 MAPK on cell cycle regulators plays a crucial role in oncogene-induced senescence involved in the suppression of tumorigenesis and replicative senescence (18) . Indeed, we found that fucoidan induced the activation of p38 protein and mRNA in HepG2 cells. Our results show that activation of p38 leads to increased expression of p16 INK4a , similarly to previous reports on oncogene-induced senescence (19) . These studies indicate that p53 is a downstream effector of p38 MAPK, which has been proposed to function as an anti-tumorigenic defense mechanism by inducing p53 and upregulating p16 INK4a . We found that fucoidan treatment induced phosphorylation of p38 MAPK and concurrently increased p38 MAPK in HepG2 cells. Consistent with these results, a previous study determined that the anti-tumor activity of fucoidan was mediated by the induction of apoptosis through the activation of p38 MAPK in human colon carcinoma cells (37) . Interestingly, in a previous study, honokiol, a novel antitumor agent isolated from a plant, increased the phosphorylated p38 MAPK without affecting p38 expression in HepG2 cells (35) . Numerous studies have demonstrated that increased levels of phosphorylated p38 are correlated with malignancy in various cancers (38, 39) . These data support the hypothesis that fucoidan may have therapeutic potential for cancer treatment.
In summary, in HepG2 cells, it is apparent that p16
INK4a upregulation is a key event in anti-tumor activity, and that fucoidan-induced overexpression of p38 MPAK is associated with the p14
Arf -p53 pathway during apoptosis. This suggests that fucoidan treatment can induce growth-suppressive signals from both p16
INK4a -Rb and p14 Arf -p53 pathways, a valuable therapeutic strategy for cancer treatment (Fig. 4A) . However, in Chang-L cells, no increase in these pathway-related proteins was noted and no evidence for apoptosis was observed after fucoidan treatment (Fig. 4B) . Among the marine compounds, lactone spongistatin induces the degradation of XIAP (40) , an
